title: [Serological diagnosis of celiac disease].
abstract: Screening studies using high-sensitivity and specificity markers indicate a prevalence of celiac disease of up to 1% in European and North-American populations. Celiac disease is a frequent condition that has become an important public health issue. Yet the majority of cases remain undiagnosed due to the polymorphism of its clinical manifestations. The new insight in the pathogenesis of celiac disease has lead to the development of new diagnostic tools. Early screening of symptomatic patients and pre-identified at-risk groups significantly improves the quality of life while reducing morbidity and mortality. However, prophylactic benefits of early diagnosis by assessing the general population have not been shown in any study. French and Northern American scientific societies have introduced serological testing in their newly revised strategies to diagnose celiac disease. Older markers judged insufficiently accurate like anti-gliadin and anti-reticulin antibodies have recently been withdrawn from the list of reimbursed medical expenses in France. Anti-endomysium and tissue transglutaminase IgA antibodies have proven to be at this day the most sensitive and specific markers for the diagnosis and follow-up of patients on gluten-free diet, at the exception of IgA-deficient patients. Assays testing for IgG antibodies are recommended upon IgA-deficiency. Although very accurate, a better standardisation of current assays may enable serological testing to replace in a near future histological confirmation brought by small bowel biopsies which remains today the gold standard test to diagnose celiac disease. Indeed, serological testing represents and attractive alternative as it is less invasive, less expansive, laboursaving and more objective in interpretation.
authors.affiliation: Laboratoire d'immunologie et d'immunogénétique, hôpital Pellegrin, place Amélie-Raba-Léon, CHU de Bordeaux, 33076 Bordeaux cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Roujon
authors.forename: A
authors.initials: A
authors.lastname: Sarrat
authors.forename: C
authors.initials: C
authors.lastname: Contin-Bordes
authors.forename: I
authors.initials: I
authors.lastname: Pellegrin
authors.forename: G
authors.initials: G
authors.lastname: Guidicelli
authors.forename: J-L
authors.initials: JL
authors.lastname: Taupin
authors.forename: J-F
authors.initials: JF
authors.lastname: Moreau
authors.forename: P
authors.initials: P
authors.lastname: Blanco
mesh_terms: D001323:Autoantibodies / Q000276:immunology; D002446:Celiac Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*; D019204:GTP-Binding Proteins / Q000502:physiology; D005903:Gliadin / Q000276:immunology; D006801:Humans; D008403:Mass Screening / Q000379:methods; D015995:Prevalence; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D012155:Reticulin / Q000276:immunology; D012698:Serologic Tests; D011503:Transglutaminases / Q000502:physiology
chemical_list: D001323:Autoantibodies; D012155:Reticulin; D005903:Gliadin; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases; D019204:GTP-Binding Proteins